How Ocular Therapeutix Recovered From US FDA’s Second Dextenza CRL
Executive Summary
A new approach, total dedication and lots of practice made a difference for the Massachusetts start-up after FDA approval was twice deferred over manufacturing quality concerns.
You may also be interested in...
UCB Holds Breath Amid Concerns Of Second FDA Rejection Of Bimzelx
The US Food and Drug Administration has published a report after an inspection of UCB’s Belgian facility where Bimzelx is manufactured and the findings suggest that a long-awaited approval for the psoriasis drug should not be taken for granted.
Finance Watch: Have Investors Reached IPO Fatigue?
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Ocular Analyzes Particulates Root Cause After Whiffing With Steel Blade
Ocular takes another swing at resolving the manufacturing issues that resulted in a complete response letter for its Dextenza.